Human Pathology
Volume 41, Issue 5 , Pages 621-631 , May 2010

B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology

Received 1 September 2009 ,Revised 21 October 2009 ,Accepted 23 October 2009.

References 

  1. Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 2008;112:4384–4399
  2. Carbone A, Gloghini A, Serraino D, Spina M. HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS. 2009;4:3–10
  3. In:  Swerdlow SH,  Campo E,  Harris NL, et al. editor. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008;
  4. In:  Jaffe ES,  Harris NL,  Stein H,  Vardiman JW editor. Tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001;
  5. Boudova L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood. 2003;102:3753–3758
  6. Lim MS, Beaty M, Sorbara L, et al. T-cell/histiocyte-rich large B-cell lymphoma: a heterogeneous entity with derivation from germinal center B cells. Am J Surg Pathol. 2002;26:1458–1466
  7. Zhao FX. Nodular lymphocyte-predominant Hodgkin lymphoma or T-cell/histiocyte-rich large B-cell lymphoma: the problem in “grey zone” lymphomas. Int J Clin Exp Pathol. 2008;1:300–305
  8. Vanhentenrijk V, Vanden Bempt I, Dierickx D, Verhoef G, Wlodarska I, De Wolf-Peeters C. Relationship between classic Hodgkin lymphoma and overlapping large cell lymphoma investigated by comparative expressed sequence hybridization expression profiling. J Pathol. 2006;210:155–162
  9. De Wolf-Peeters C, Delabie J, Campo E, Jaffe ES, Delsol G. T cell/histiocyte-rich large B-cell lymphoma. In:  Swerdlow SH,  Campo E,  Harris NL, et al. editor. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008;p. 238–239
  10. Achten R, Verhoef G, Vanuytsel L, De Wolf-Peeters C. Histiocyte-rich, T-cell-rich B-cell lymphoma: a distinct diffuse large B-cell lymphoma subtype showing characteristic morphologic and immunophenotypic features. Histopathology. 2002;40:31–45
  11. Poppema S, Delsol G, Pileri SA, Stein H. Nodular lymphocyte predominant Hodgkin lymphoma. In:  Swerdlow SH,  Campo E,  Harris NL, et al. editor. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008;p. 323–325
  12. Carbone A, Gloghini A, Gruss HJ, Pinto A. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol. 1995;147:912–922
  13. Carbone A, Gloghini A, Aldinucci D, Gattei V, Dalla-Favera R, Gaidano G. Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. Br J Haematol. 2002;117:366–372
  14. Rudiger T, Jaffe ES, Delsol G, et al. Workshop report on Hodgkin's disease and related diseases (‘grey zone’ lymphoma). Ann Oncol. 1998;9(Suppl 5):S31–S38
  15. Brune V, Tiacci E, Pfeil I, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med. 2008;205:2251–2268
  16. Liso A, Capello D, Marafioti T, et al. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. Blood. 2006;108:1013–1020
  17. Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29:1411–1421
  18. Garcia JF, Mollejo M, Fraga M, et al. Large B-cell lymphoma with Hodgkin's features. Histopathology. 2005;47:101–110
  19. Jaffe ES, Stein H, Swerdlow SH, Campo E, Pileri SA, Harris NL. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma. In:  Swerdlow SH,  Campo E,  Harris NL, et al. editor. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008;p. 267–268
  20. Poppema S, Kluiver JL, Atayar C, et al. Report: workshop on mediastinal grey zone lymphoma. Eur J Haematol Suppl. 2005;45–52
  21. Lamarre L, Jacobson JO, Aisenberg AC, Harris NL. Primary large cell lymphoma of the mediastinum. A histologic and immunophenotypic study of 29 cases. Am J Surg Pathol. 1989;13:730–739
  22. Pileri SA, Gaidano G, Zinzani PL, et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol. 2003;162:243–253
  23. Gaulard P, Harris NL, Pileri SA, et al. Primary mediastinal (thymic) large B-cell lymphoma. In:  Swerdlow SH,  Campo E,  Harris NL, et al. editor. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008;p. 250–251
  24. Ritz O, Leithauser F, Hasel C, et al. Downregulation of internal enhancer activity contributes to abnormally low immunoglobulin expression in the MedB-1 mediastinal B-cell lymphoma cell line. J Pathol. 2005;205:336–348
  25. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851–862
  26. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102:3871–3879
  27. Barth TF, Leithauser F, Moller P. Mediastinal B-cell lymphoma, a lymphoma type with several characteristics unique among diffuse large B-cell lymphomas. Ann Hematol. 2001;80(Suppl 3):B49–B53
  28. Brauninger A, Schmitz R, Bechtel D, Renne C, Hansmann ML, Kuppers R. Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer. 2006;118:1853–1861
  29. Mancao C, Altmann M, Jungnickel B, Hammerschmidt W. Rescue of “crippled” germinal center B cells from apoptosis by Epstein-Barr virus. Blood. 2005;106:4339–4344
  30. Carbone A, Gloghini A, Cabras A, Elia G. The Germinal centre-derived lymphomas seen through their cellular microenvironment. Br J Haematol. 2009;145:468–480
  31. Stein H, Delsol G, Pileri SA, Weiss LM, Poppema S, Jaffe ES. Classical Hodgkin lymphoma, introduction. In:  Swerdlow SH,  Campo E,  Harris NL, et al. editor. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008;p. 326–329
  32. Chui DT, Hammond D, Baird M, Shield L, Jackson R, Jarrett RF. Classical Hodgkin lymphoma is associated with frequent gains of 17q. Genes Chromosomes Cancer. 2003;38:126–136
  33. Feuerhake F, Kutok JL, Monti S, et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. 2005;106:1392–1399
  34. Guiter C, Dusanter-Fourt I, Copie-Bergman C, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood. 2004;104:543–549
  35. Melzner I, Bucur AJ, Bruderlein S, et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood. 2005;105:2535–2542
  36. Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006;25:2679–2684
  37. Ritz O, Guiter C, Castellano F, et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood. 2009;114:1236–1242
  38. Renne C, Willenbrock K, Martin-Subero JI, et al. High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. Leukemia. 2007;21:780–787
  39. de Leval L, Hasserjian RP. Diffuse Large B-Cell Lymphomas and Burkitt lymphoma. Hematol Oncol Clin North Am. 2009;23:791–827
  40. Kluin PM, Harris NL, Stein H, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In:  Swerdlow SH,  Campo E,  Harris NL, et al. editor. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008;p. 265–266
  41. Leoncini L, Raphael M, Stein H, Harris NL, Jaffe ES, Kluin PM. Burkitt lymphoma. In:  Swerdlow SH,  Campo E,  Harris NL, et al. editor. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008;p. 262–264
  42. Chuang SS, Ye H, Du MQ, et al. Histopathology and immunohistochemistry in distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starry-sky pattern: a comparative study with EBER and FISH. Am J Clin Pathol. 2007;128:558–564
  43. Boerma EG, Siebert R, Kluin PM, Baudis M. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of today's knowledge. Leukemia. 2009;23:225–234
  44. Gurbaxani S, Anastasi J, Hyjek E. Diffuse large B-cell lymphoma—more than a diffuse collection of large B cells: an entity in search of a meaningful classification. Arch Pathol Lab Med. 2009;133:1121–1134
  45. Hyo R, Tomita N, Takeuchi K, et al. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hematol Oncol. 2009;
  46. Ci W, Polo JM, Cerchietti L, et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood. 2009;113:5536–5548
  47. Saito M, Novak U, Piovan E, et al. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2009;106:11294–11299
  48. Hartmann EM, Ott G, Rosenwald A. Molecular biology and genetics of lymphomas. Hematol Oncol Clin North Am 2008;22:807, 23, vii.
  49. Au WY, Horsman DE, Gascoyne RD, Viswanatha DS, Klasa RJ, Connors JM. The spectrum of lymphoma with 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases. Leuk Lymphoma. 2004;45:519–528
  50. Said J. Diffuse aggressive B-cell lymphomas. Adv Anat Pathol. 2009;16:216–235
  51. Haralambieva E, Boerma EJ, van Imhoff GW, et al. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol. 2005;29:1086–1094
  52. Bellan C, Lazzi S, De Falco G, Rogena EA, Leoncini L. Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach. Hematol Oncol. 2009;27:182–185
  53. Sevilla DW, Gong JZ, Goodman BK, et al. Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation. Am J Clin Pathol. 2007;128:981–991
  54. Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92:1335–1342
  55. Keller CE, Nandula S, Fisher J, et al. The spectrum of B-cell non-Hodgkin lymphomas with dual IgH-BCL2 and BCL6 translocations. Am J Clin Pathol. 2008;130:193–201
  56. Hasserjian RP, Ott G, Elenitoba-Johnson KS, Balague-Ponz O, de Jong D, de Leval L. Commentary on the WHO classification of tumors of lymphoid tissues (2008): “gray zone” lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma. J Hematop. 2009;2:89–95
  57. Zinzani PL, Martelli M, Magagnoli M, et al. Anaplastic large cell lymphoma Hodgkin's-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapy. Blood. 1998;92:790–794
  58. Calvo KR, Traverse-Glehen A, Pittaluga S, Jaffe ES. Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma. Adv Anat Pathol. 2004;11:227–238
  59. Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008;112:2248–2260
  60. Macpherson N, Lesack D, Klasa R, et al. Small noncleaved, non-Burkitt's (Burkit-like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol. 1999;17:1558–1567
  61. McClure RF, Remstein ED, Macon WR, et al. Adult B-cell lymphomas with Burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol. 2005;29:1652–1660

☆ This work was supported in part by a Grant from the Ministero della Salute, Rome, within the framework of the “Progetto Integrato Oncologia-Advanced Molecular Diagnostics” project (RFPS-2006-2-339723.2) (to A.Car.).

PII: S0046-8177(10)00049-3

doi: 10.1016/j.humpath.2009.10.027

Human Pathology
Volume 41, Issue 5 , Pages 621-631 , May 2010

Article Tools

* Image Usage & Resolution